Scythian Biosciences Corp. (TSX.V: $SCYB.V) Retains The Weinberg Group To Provide FDA Consulting Services

Scythian Biosciences Corp. (TSX.V: $SCYB.V) Retains The Weinberg Group To Provide FDA Consulting Services

TORONTO - August 28, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) is pleased to announce that it has entered into a consulting arrangement with The Weinberg Group and has retained The Weinberg Group's services for assistance with the Company's FDA application process, including pre-IND and IND consulting services.

Read this news in full at

http://www.investorideas.com/CO/SCYB/news/2017/08281FDAConsulting.asp

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian Biosciences Corp. (TSX.V: SCYB)

is a Featured biotech and marijuana company on Investorideas.com

Visit Profile page: http://www.investorideas.com/CO/SCYB/

Get News Alerts on Scythian Biosciences Corp.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country

Video News; Scythian Biosciences (TSX.V: $SCYB.V) Discusses #Cannabinoid-based Treatment for #Concussion and Traumatic Brain Injury

Video News; Scythian Biosciences (TSX.V: $SCYB.V) Discusses #Cannabinoid-based Treatment for #Concussion and Traumatic Brain Injury

August 18, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks releases a video/ interview featuring David Schrader, Chief Operating Officer of Scythian Biosciences (TSX.V: SCYB), a company developing a drug regimen for concussion and traumatic brain injury using a cannabinoid-based combination drug therapy.

Watch video: https://www.youtube.com/watch?v=DaNLaGh0G-w

Read this news in full at http://www.investorideas.com/CO/SCYB/news/2017/08181Video.asp

Scythian ( http://scythianbio.com/) is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

About Investorideas.com - News that Inspires Big Ideas

www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Listen to original podcast: http://www.investorideas.com/CO/SCYB/news/2017/08161COOTalks.asp

The Investorideas.com podcasts are also available on iTunes, Tunein, Sticher. Spreaker.com, iHeart.com  and Google Play Music.

Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

http://www.investorideas.com/rss/feeds/Podcasts.xml

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Visit Scythian Biosciences (TSX.V: SCYB  )Profile page: http://www.investorideas.com/CO/SCYB/

Contact Investorideas.com

800-665-0411

Scythian Biosciences Corp. (TSXV: $SCYB.V) Retains Hybrid Financial Ltd. for Investor Relations Activities

Scythian Biosciences Corp. (TSXV: $SCYB.V) Retains Hybrid Financial Ltd. for Investor Relations Activities

TORONTO - August 17, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) announces that it has retained the services of Hybrid Financial Ltd. ("Hybrid Financial") for strategic investor relations activities. The initiatives includes marketing and investor relations services for the Company.

Read this news in full athttp://www.investorideas.com/CO/SCYB/news/2017/08171InvestorRelations.asp

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Scythian Biosciences Corp. (TSX.V: SCYB)

is a Featured biotech and marijuana company on Investorideas.com

Visit Profile page: http://www.investorideas.com/CO/SCYB/

Get News Alerts on Scythian Biosciences Corp.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

COO of Scythian Biosciences (TSX.V: $SCYB.V) Talks about Treatment for #Concussion and traumatic brain injury with #Cannabinoid-based combination drug therapy

COO of Scythian Biosciences (TSX.V: $SCYB.V) Talks about Treatment for #Concussion and traumatic brain injury with  #Cannabinoid-based combination drug therapy

August 16, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues a  podcast interview with David Schrader, Chief Operating Officer at Scythian Biosciences Corp. (TSXV: SCYB).

Listen to the full podcast interview :

http://www.investorideas.com/Audio/Podcasts/081417-Scythian-Interview.mp3

Read this news in full at

http://www.investorideas.com/CO/SCYB/news/2017/08161COOTalks.asp

Scythian ( http://scythianbio.com/)  is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

About Investorideas.com - News that Inspires Big Ideas

www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

The Investorideas.com podcasts are also available on iTunes, Tunein, Sticher. Spreaker.com, iHeart.com  and Google Play Music.

Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

http://www.investorideas.com/rss/feeds/Podcasts.xml

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details -http://www.investorideas.com/About/News/Clientspecifics.asp

Visit Profile page: http://www.investorideas.com/CO/SCYB/

Contact Investorideas.com

800-665-0411

Audio Interview with David Schrader, Chief Operating Officer at Scythian Biosciences (TSX.V: $SCYB.V)

Audio Interview with David Schrader, Chief Operating Officer at Scythian Biosciences (TSX.V: $SCYB.V)

August 15, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues an exclusive podcast interview with David Schrader, Chief Operating Officer at Scythian Biosciences Corp.  (TSX.V: SCYB).

Scythian Biosciences Corp. seeks to develop the first accepted drug regimen for concussion and traumatic brain injury with their cannabinoid-based combination drug therapy.

Read this news in full at

http://www.investorideas.com/CO/SCYB/news/2017/08151Podcast.asp

  

Listen to the full podcast interview :

http://www.investorideas.com/Audio/Podcasts/081417-Scythian-Interview.mp3

Scythian ( http://scythianbio.com/)  is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

About Investorideas.com - News that Inspires Big Ideas

www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

The Investorideas.com podcasts are also available on iTunes, Tunein, Sticher. Spreaker.com, iHeart.com  and Google Play Music.

Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

http://www.investorideas.com/rss/feeds/Podcasts.xml

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details -http://www.investorideas.com/About/News/Clientspecifics.asp

Visit Profile page: http://www.investorideas.com/CO/SCYB/

Contact Investorideas.com

800-665-0411

Concussion-focused Scythian (TSXV: $SCYB,V) sets market debut

Concussion-focused Scythian  (TSXV: $SCYB,V) sets market debut on the TSX Venture Exchange
The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets.

Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of the company’s outstanding shares, with the rest locked in escrow by the TSX Venture Exchange.
http://www.innovateli.com/concussion-focused-scythian-sets-stock-market-debut/

CORRECTION: Tap and Barrel’s Olympic Village Chef Has Fight Set for July 27^th at Annual Aprons for Gloves Restaurant Rumble; #TAPvillage, #AFG

Tickets at Ticketmaster - Rumble17

Vancouver BC – July 17, 2017 (Investorideas.com Newswire) Correction to previous news;  Local Vancouver chef Taylor Van Zant from the Tap & Barrel in Olympic Village will take on  Bryn Thomas at the  6th Annual Aprons for Gloves Restaurant Rumble event  on  July 27^th at the Commodore Ballroom – 868 Granville St. Vancouver, BC.  Aprons for Gloves Boxing Association is a non-profit organization focused on providing community outreach through the sport of boxing.

Taylor says,” I'm putting my face on the line at Restaurant Rumble 2017 in support of Vancouver's Downtown East Side.”

Read this news in full at http://www.investorideas.com/news/2017/sports/07171Correction.asp

Aprons for gloves Men's 185 - 200lbs - Bryn Thomas VS Taylor Van Zant

Details:

RR17 Fight Night

Date:  July 27, 2017 Time: Daytime Undercards & Evening Title Fights Location: Commodore Ballroom – 868 Granville St. Vancouver, BC Details: Restaurant Rumble 2017: Vancouver's 6th Annual Boxing Fundraiser. Tickets: Ticketmaster - Rumble17

Buy tickets https://www.ticketmaster.ca/search?tm_link=tm_homeA_header_search&user_input=restaurant+rumble+2017&q=restaurant+rumble+2017

In order to attend training, each fighter is required to raise $2000 for charity before they can compete at the Rumble and Taylor is getting close to reaching his $2000 goal as he trains for the fight .

Founded in 2012, Aprons for Gloves Boxing Association is a non-profit organization focused on providing community outreach through the sport of boxing. Based in Vancouver’s Downtown Eastside, the organization was developed by a small group of professionals and entrepreneurs who seized an opportunity to re-establish a historic boxing program for at-risk women and youth. The program offers free mentorship and training to individuals who may otherwise not have the resources or support to participate in such activities.

The sport of boxing teaches discipline, respect, hard work and self-control. Training results in positive self-esteem, good health and camaraderie for its practitioners.

Learn more and donate here to Taylor’s event for Aprons for Gloves :

https://fundrazr.com/tapnbarrelchef?fb_ref=share__76dLd5&ref=ab_06e2v5

Aprons for Gloves Boxing Association

@eastsideboxing1 #AFG #RR17 #FUNdraising

http://apronsforgloves.com/

 Tap and Barrel, Olympic Village http://tapandbarrel.com/

Video: Aprons For Gloves - Restaurant Rumble 2014 - Intro to the Title Fights

Watch the video : https://www.youtube.com/watch?v=hh4gM5vSapQ

Restaurant Rumble 2017

Every year bartenders, chefs, dishwashers, servers, baristas and all sorts of individuals from the Gastown community get together to train at the Eastside Boxing Club to fight in Restaurant Rumble.

Contact at

https://fundrazr.com/tapnbarrelchef?fb_ref=share__76dLd5&ref=ab_06e2v5

Sports Stocks

Like Sports Stocks? View our Sports Stocks Directory